e-learning
resources
2021
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
A systematic review of the diagnostic accuracy of volatile organic compounds in airway diseases and their relation to markers of type-2 inflammation
Wadah Ibrahim, Sushiladevi Natarajan, Michael Wilde, Rebecca Cordell, Paul S. Monks, Neil Greening, Christopher E. Brightling, Rachael Evans, Salman Siddiqui
Source:
ERJ Open Res, 7 (3) 00030-2021; 10.1183/23120541.00030-2021
Journal Issue:
July
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Wadah Ibrahim, Sushiladevi Natarajan, Michael Wilde, Rebecca Cordell, Paul S. Monks, Neil Greening, Christopher E. Brightling, Rachael Evans, Salman Siddiqui. A systematic review of the diagnostic accuracy of volatile organic compounds in airway diseases and their relation to markers of type-2 inflammation. ERJ Open Res, 7 (3) 00030-2021; 10.1183/23120541.00030-2021
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Respiratory sequelae of preterm birth across the life span
Time to breathe: Challenges in the successful management of asthma during conception, pregnancy and delivery
Related content which might interest you:
Volatile organic compounds and risk of asthma and allergy: a systematic review
Source: Eur Respir Rev 2015; 24: 92-101
Year: 2015
Interpretation of exhaled volatile organic compounds
Source: Eur Respir Monogr 2010; 49: 115-129
Year: 2010
Volatile organic compounds may provide a new and promising tool for diagnosing interstitial lung diseases
Source: Annual Congress 2012 - Exhaled biomarkers in airway diseases
Year: 2012
Integrating monitoring of volatile organic compounds (VOCs) in asthma and COPD into the routine lung function
Source: International Congress 2015 – The next generation of lung function tests
Year: 2015
Multiple detectable exhaled volatile organic compounds (vocs) may serve as potential inflammatory biomarkers in COPD
Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment
Year: 2009
Overview and history of different ways of assessing and monitoring inflammatory airway diseases
Source: International Congress 2017 – PG6 Assessing and monitoring airway inflammation in asthma and chronic obstructive pulmonary disease
Year: 2017
Usefulness of physiological tests of small airways function in diagnosing asthma: a systematic review
Source: Virtual Congress 2020 – Lung function diagnostics
Year: 2020
Breath volatile organic compounds and inflammatory markers in adult asthma patients: negative results from the ALLIANCE cohort
Source: Eur Respir J, 57 (2) 2002127; 10.1183/13993003.02127-2020
Year: 2021
Limited clinical value of exhaled volatile organic compound measurements in childhood asthma
Source: ERJ Open Res, 4 (4) 00026-2018; 10.1183/23120541.00026-2018
Year: 2018
Value of exhaled volatile organic compounds in monitoring airway disease
Source: School Course 2013 - Monitoring of asthma, COPD and other airway diseases
Year: 2013
Clinical and inflammatory phenotyping by breathomics in chronic airway diseases irrespective of the diagnostic label
Source: Eur Respir J, 51 (1) 1701817; 10.1183/13993003.01817-2017
Year: 2018
Non-targeted integrative multi-omics approaches on sputum reveal potential diagnostic and monitoring biomarkers for respiratory diseases
Source: International Congress 2017 – Novel molecular and genetic targets in COPD
Year: 2017
Comparison of exhaled biomarkers to other markers of airway diseases
Source: School Course 2013 - Monitoring of asthma, COPD and other airway diseases
Year: 2013
Volatile organic compounds in COPD: Is hexanal an inflammation biomarker?
Source: International Congress 2016 – The future of lung function is beginning now
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept